MAIA Biotechnology, Inc. Form 8-K Summary
Business Context and Reporting Period
MAIA Biotechnology, Inc. (MAIA), a Delaware corporation, filed this Current Report on Form 8-K on March 27, 2026. The filing discloses the presentation of a scientific poster at the European Lung Cancer Congress 2026 (ELCC) in Copenhagen, Denmark. The Company is classified as an emerging growth company.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on a regulatory disclosure regarding clinical trial data.
Material Changes
No material financial changes versus prior periods are reported in this filing. The primary event is the dissemination of clinical data regarding the Company's lead candidate, Ateganosine.
Guidance, Outlook, and Management Commentary
- Clinical Update: The Company presented a poster titled "Sustained Response and Long-Term Therapeutic Benefits Beyond Treatment Cessation in Abstract NSCLC Relapsed-Patients Treated with Ateganosine and ICI in the THIO-101 Trial."
- Forward-Looking Statements: The poster contains forward-looking statements. Management advises investors not to place undue reliance on these statements.
- Exhibits: The full poster is filed as Exhibit 99.1 and is incorporated by reference.
Investor Verification Checklist
- Review Exhibit 99.1 (the Poster) for specific clinical data points regarding the THIO-101 trial.
- Verify the definition of "Sustained Response" and "Long-Term Therapeutic Benefits" as used in the poster.
- Check for any subsequent press releases or presentations detailing the statistical significance of the reported results.
- Confirm the Company's cash runway and funding status in the most recent 10-Q or 10-K, as this 8-K does not provide liquidity metrics.